Over the last 5 years, insiders at Oric Pharmaceuticals have traded over 33,873,532$ worth of Oric Pharmaceuticals stock and bought 1,422,500 units worth 12,330,600$ . The most active insiders traders include Advisors Llc Orbi Med Capit...、Carl L Gordon、Peter Svennilson. On average, Oric Pharmaceuticals executives and independent directors trade stock every 29 days with the average trade being worth of 996,237$. The most recent stock trade was executed by Lori Anne Kunkel on 3 June 2024, trading 20,500 units of ORIC stock currently worth 76,875$.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has collaboration and license agreement with Voronoi, Inc.; and Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Oric Pharmaceuticals executives and other stock owners filed with the SEC include: